Clinical Trial Update: Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of mavorixafor in WHIM syndrome. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Whim Syndrome

Drugs mentioned

• Mavorixafor (mavorixafor)

Snippet

Sponsor: X4 Pharmaceuticals | Conditions: WHIM Syndrome | Phase 3 | Status: ACTIVE_NOT_RECRUITING